Free Shipping on Orders Over $200
The Purest Peptides. Period.
Lab Tested and Shipped from the USA
Peptide Blend
Ipamorelin + Tesamorelin Blend
$90.00
Quantity
Discounted Price
5–9
$84.60 each (save $5.40/unit)
10+
$81.00 each (save $9.00/unit)
Ships in 1–2 business days. Most US orders arrive in 3–5. Free shipment protection on every order
For Research Use Only
Third-party tested · CoA on file Discreet, tracked shipping Free shipping over $200 Members earn 5% back in store credit
Class Peptide Blend
Also Known As Ipamorelin + Tesamorelin Blend
Purity ≥99%
Amino Acid Sequence Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Tesamorelin: trans-3-hexenoic acid-modified GHRH(1-44)
Research Areas
Synergistic GH release GHRH/GHSR agonism Pituitary signaling Growth hormone biology
What is IPA/TESA Blend?
The IPA/TESA Blend combines ipamorelin, a selective GH secretagogue receptor (GHSR) agonist, with tesamorelin, a stabilized GHRH analog, in a single research formulation. Like the Ipamorelin + CJC-1295 blend, this combination exploits the well-characterized synergy between GHRH and GHSR signaling pathways at the pituitary. Tesamorelin (trans-3-hexenoic acid modified GHRH 1-44) is an FDA-approved GHRH analog with enhanced stability compared to native GHRH. When paired with ipamorelin, it provides GHRH receptor activation that synergizes with ipamorelin’s GHSR activation for amplified GH release. The key difference from the IPA/CJC blend is the GHRH component — tesamorelin is a full-length 44-amino acid GHRH analog compared to the 29-amino acid CJC-1295 No DAC, and it carries FDA approval for clinical use in HIV-associated lipodystrophy.
Mechanism of Action
The IPA/TESA Blend has been investigated for its dual activation of GHRH receptor and GHSR signaling in pituitary somatotrophs. Tesamorelin activates the GHRH receptor through Gs-coupled adenylyl cyclase signaling, increasing cAMP and activating PKA, which primes GH secretory vesicles. Ipamorelin activates GHS-R1a through Gq-coupled phospholipase C, increasing IP3 and intracellular calcium, which triggers vesicle fusion and exocytosis. Researchers observed that this convergent signaling produces synergistic GH release. Tesamorelin’s trans-3-hexenoic acid modification at the N-terminus protects against DPP-IV cleavage, extending its effective half-life compared to native GHRH. Studies suggest that the full 44-amino acid sequence of tesamorelin may engage additional receptor contacts compared to truncated GHRH analogs. Ipamorelin’s selectivity ensures GH release without cortisol, prolactin, or significant appetite stimulation.
Published Research
Tesamorelin Clinical Data
Falutz et al. (2007) investigated tesamorelin in a randomized clinical trial and demonstrated its ability to stimulate endogenous GH secretion and modulate visceral adipose tissue parameters, establishing the clinical profile of this blend component [1].
GHRH-GHSR Synergy
Bowers et al. (1990) demonstrated the synergistic interaction between GHRH and GH secretagogues at the pituitary level, providing the mechanistic basis for combining tesamorelin with ipamorelin [2].
Ipamorelin Selectivity
Raun et al. (1998) characterized ipamorelin’s selectivity profile, demonstrating GH release without significant cortisol or prolactin co-secretion [3].
Product Specifications
Product IPA/TESA Blend Lyophilized Powder Available Sizes IPA 5mg / TESA 10mg (15mg) Purity ≥99% (HPLC verified) Sequence Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Tesamorelin: trans-3-hexenoic acid-modified GHRH(1-44) Appearance White lyophilized powder in glass vial Storage Store lyophilized at -20°C. Reconstituted solution at 2-8°C, use within 14 days. Testing Third-party tested — Certificate of Analysis available
Storage & Stability
Avoid freeze/thaw cycles Protect from light Keep cold
Lyophilized powder Store at -20°C
Reconstituted 2–8°C, use within 14 days
Store lyophilized at -20°C. Reconstituted solution at 2-8°C, use within 14 days.
Certificate of Analysis
Third-Party Tested HPLC-UV + Mass Spec Identity & Purity
Every batch is third-party tested to ≥99% purity before release
Purity (HPLC-UV / MS) ≥99% Pass Identity Confirmed by HPLC-UV / MS Verified Appearance White lyophilized powder in glass vial Pass
Third-party tested by HPLC-UV coupled with mass spectrometry. A lot-specific Certificate of Analysis is available on request.
Frequently Asked Questions
The IPA/TESA Blend combines ipamorelin (GHSR agonist) with tesamorelin (GHRH analog) for synergistic GH secretagogue research.
The GHRH component differs u2014 tesamorelin is a full 44-amino acid GHRH analog with FDA approval, while CJC-1295 No DAC is a 29-amino acid modified GHRH fragment.
Store lyophilized at -20°C. Once reconstituted, store at 2-8°C and use within 14 days.
Tesamorelin is a stabilized GHRH(1-44) analog with a trans-3-hexenoic acid modification. It is FDA-approved for clinical use and stimulates endogenous GH secretion.
Yes, both Ipamorelin and Tesamorelin are available as individual products.
References
1
Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. PMID: 18057338 View source
2
Bowers CY, et al. On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology. 1990;128(4):2027-2035.
3
Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822 View source
Customer Reviews
4.9
Based on 11 reviews
M
Quick delivery and the quality is consistently high.
S
This vendor sets the standard. Highly recommend.
M
This vendor sets the standard. Highly recommend.
H
Impressed with the quality. Packaging was professional.
A
Outstanding quality. This is my go-to source now.
Join the research list — 15% off your first order
New compounds, COA releases, and research updates. No spam, unsubscribe anytime.
You're viewing: IPA/TESA Blend $90.00
Rated 4.90 out of 5
Select options